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Abstract
Propofol is the most important intravenous general anesthetic in current clinical use. It acts by 
potentiating GABAA receptors, but where it binds to this receptor is not known and has been a 
matter of some controversy. We have synthesized a novel propofol analogue photolabeling reagent 
that has a biological activity very similar to that of propofol. We confirmed that this reagent 
labeled known propofol binding sites in human serum albumin which have been identified using 
X-ray crystallography. Using a combination of the protiated label and a deuterated version, and 
mammalian receptors labeled in intact membranes, we have identified a novel binding site for 
propofol in GABAA receptors consisting of both β3 homopentamers and α1β3 heteropentamers. 
The binding site is located within the β subunit, at the interface between the transmembrane 
domains and the extracellular domain, and lies close to known determinants of anesthetic 
sensitivity in transmembrane segments TM1 and TM2.
Propofol is the world’s most widely used intravenous general anesthetic, but how it acts at 
the molecular level is unknown. A key role for the GABAA receptor in the actions of 
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propofol seemed likely ever since the demonstration1 that clinically relevant concentrations 
of the drug markedly enhance the GABA-induced chloride current. That this receptor is the 
most important target for propofol is now beyond doubt following the work of Jurd et al.2 
who showed that a point mutation in the β3 subunit of the receptor in a knock-in mouse is 
sufficient to abolish the actions of propofol in preventing a response to a painful stimulus, 
and to greatly reduce its effects in causing a loss of righting reflex (a surrogate for loss of 
consciousness). Although it is generally agreed that the principal target for propofol is the 
GABAA receptor, where it binds to this receptor, and how binding is translated into an 
enhanced chloride current is not clear.
A complete picture of how propofol acts requires a knowledge of where it binds to its 
targets. Because no high-resolution X-ray crystal structure yet exists for a mammalian 
GABAA receptor, most work that has aimed at identifying the binding site or sites has been 
indirect. Work on subunit selectivity shows that homomeric β3 receptors will form a 
complex that provides a binding site for propofol3,4 with an affinity that is little different 
from that of the intact αβγ receptor3. While the presence, or isoform, of the α, γ and δ 
subunits have all been shown to affect propofol modulation of the GABAA receptor5–8, it 
seems likely that the propofol binding site involves the β subunit.
This conclusion is strengthened by site-directed mutagenesis which has provided a wealth of 
information on how mutations in specific subunits can affect anesthetic action9. While 
mutations in the α10 and γ11 subunits have been shown to change propofol’s modulation of 
the GABAA receptor, most work has focused on mutations in the β subunit. Amino acids in 
the β112, β213–17 and β318 subunits have been found that, when mutated, influence propofol’s 
actions. These mutations, however, are distributed throughout the membrane-spanning 
region of the receptor, being found in TM114, TM215,18, TM312,13,15,18 and TM416 as well 
as in the extracellular domain17. The question then remains, which if any of these amino 
acids form part of a binding site? A crystal structure of a proton-activated bacterial 
homologue of the GABAA receptor, GLIC, shows a propofol binding site buried between 
these four helices19. This channel, however, is inhibited by propofol, so the relationship 
between this site and the potentiating site in mammalian channels remains unclear.
One approach to this problem involves mutating amino acids at a putative propofol binding 
site to cysteine residues, and then probing that site using chemical reagents that bind to 
cysteine irreversibly20. This is an elegant approach and has been used to argue that a 
propofol binding site must exist close to the middle of TM3. Unfortunately, it suffers from 
the same problem that bedevils the interpretation of site-directed mutagenesis - are the 
observed effects a consequence of allosteric conformational changes? For example, while 
propofol does indeed block the chemical modification of a cysteine mutated into the middle 
of TM320, is this due to a direct steric interaction or an effect of propofol binding 
elsewhere21?
An alternative, and direct, method of identifying a drug binding site is to use an analogue of 
the drug that contains a photoaffinity group whose activation by light results in irreversible 
covalent binding. This requires, of course, that the photoaffinity analogue of the drug 
resembles the parent compound sufficiently closely so that it binds in exactly the same 
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location. Additionally, the photolabeling reagent must preferentially participate in inter-
molecular crosslinking rather than intra-molecular rearrangement; this is a difficult 
condition to achieve for propofol whose simple aromatic structure makes internal 
rearrangement following photoactivation highly likely. In addition to these problems, 
separating peptides from a multimeric transmembrane protein such as the GABAA receptor 
in sufficient quantities to enable a specific labeled amino acid to be identified is very 
challenging22. In this paper we show how we have solved these problems by synthesizing 
novel protiated and deuterated versions of a propofol diazirine with properties very similar 
to propofol, using them to photolabel GABAA receptors expressed in intact membranes and 
utilizing high-resolution mass spectroscopy23 to identify sites of photolabel incorporation. 
Using this approach we have identified a novel binding site for propofol.
RESULTS
Synthesis and characterization of propofol photolabels
We synthesized four different putative propofol photolabels, each of which incorporated a 
trifluoromethyl diazirine group in either the ortho (1), meta (2) or para (3, 4) positions 
(Supplementary Results, Supplementary Fig. 1). Only the analogue with a trifluoromethyl 
diazirine group at the ortho position (1) replacing one of the two isopropyl groups (Fig. 1a) 
proved to be an effective photolabel, with essentially 100% incorporation into ethanol, as 
well as being very similar to the parent compound propofol in its ability to directly activate 
and potentiate GABAA receptors (Fig. 1b). The other analogues were either very poor 
photolabels (the para-substituted derivatives; 3, 4) or were virtually inactive in potentiating 
GABAA receptors (the meta-substituted derivative; 2).
The peak absorbance of ortho-propofol diazirine (λmax=283 nm; ε =1970 ± 20 M−1 cm−1) 
was very similar to that of propofol (λmax=275 nm; ε =2490 ± 90 M−1 cm−1) but, in 
addition, there was an absorption band between 320 and 360 nm due to the diazirine group 
(Fig. 1c), with an extinction coefficient at 350 nm of 40.5 ± 2.5 M−1 cm−1. Following 
exposure of an ethanolic solution of ortho-propofol diazirine to light (>320 nm) from a 
mercury-xenon arc lamp, changes in the spectrum occurred with a halftime of 23.8 ± 1.0 s. 
In the absence of light, ortho-propofol diazirine was stable over several hours at room 
temperature, and several months at −20°C.
As a prelude to our attempts to label GABAA receptors, we examined the concentration-
dependent modulation of [35S]TBPS binding to GABAA β3 homomeric receptors expressed 
in Sf9 cells, and the EC50 concentration for potentiation of currents elicited by an EC60 
concentration of GABA in α1β3 heteromers expressed in HEK cells. ortho-Propofol 
diazirine inhibited TBPS binding to β3 homomers with an IC50 of 2.9 ± 0.4 μM (Fig. 1d), 
similar to previous reports with propofol3,4. The EC50 for the potentiation of GABA-
induced currents mediated by α1β3 heteromers (Fig. 1e) was comparable, at 1.7 ± 0.7 μM.
In order to compare the anesthetic potency of propofol and ortho-propofol diazirine in 
animals, we determined the ED50 doses needed to induce loss of righting reflex (LORR) in 
Sprague-Dawley rats. Various doses of both compounds were administered by tail-vein 
injection and dose-response curves constructed using the method of Waud24. Both propofol 
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and ortho-propofol diazirine were able to cause reversible loss of righting reflex at 
comparable concentrations (Fig. 1f)
Labeling human serum albumin
To further validate the use of ortho-propofol diazirine to identify propofol binding sites in 
GABAA receptors, we tested its ability to label known propofol binding sites that have been 
identified in the high-resolution crystal structure25 of the soluble protein human serum 
albumin (HSA). The structure of HSA with propofol bound was solved at a resolution of 2.4 
Å, and showed two propofol binding sites: propofol site 1 in subdomain IIIA of HSA and 
propofol site 2 in subdomain IIIB. We carried out labeling experiments with HSA in the 
presence of either the protiated or the deuterated forms of ortho-propofol diazirine to see if 
these known sites could be identified.
We exposed HSA to light with wavelengths >320 nm in the absence (control) or presence of 
either the protiated or deuterated forms of ortho-propofol diazirine, then analyzed tryptic 
digests of the samples using LC-MS26. In the control samples, tandem spectra (MS2) 
unambiguously identified peptides that contained 569 of the 585 amino acids in HSA (97% 
coverage; Supplementary Fig. 2). In some cases, labeling of peptides could be detected by 
changes in absorbance at 214 and 280 nm in the HPLC traces. Our search of the mass 
spectrometric data for labeled peptides was greatly facilitated by the combined use of the 
protiated and deuterated forms of the photolabel. This is because, while the isotopic 
distributions of most peptides would be expected to be very similar, whether or not they 
labeled with the protiated ortho-propofol diazirine (see e.g. Figs. 2a,b), a peptide labeled 
with our deuterated version (which contains a known distribution of d0, d1 and d2 species) is 
characteristically different and immediately recognizable (see e.g. Fig. 2c). Hence it was 
relatively easy to identify the peptides that had been labeled.
A number of peptides were identified whose molecular weights had increased by the 
expected amount (216.1 Da) on labeling with the protiated ortho-propofol diazirine and 
which also showed the characteristic isotopic distribution when labeled with the deuterated 
version of the photolabel. In all cases the labeled peptide adduct eluted later than the parent 
peptide during HPLC separation, consistent with an increase in hydrophobicity. As 
expected, we observed specific labeling of amino acids in the two known propofol binding 
sites 1 and 2 (Figs. 2d–h). In the highest affinity propofol site25, site 1, a single amino acid 
(Y411) was labeled (Fig. 2d,g), while in the lower affinity site25, propofol site 2, four amino 
acids (K525, H535, K536, K541) were labeled (Fig. 2e,h). Interestingly, we were not able to 
show any measurable labeling of HSA by meta-propofol diazirine (2), indicating that meta-
substituted derivatives of propofol may not bind at the same sites as the parent compound.
Labeling GABAA receptors
To identify propofol binding sites on GABAA receptors, membranes were prepared from 
Sf9 cells transfected with epitope-tagged α1strep and β3His subunits27; these membranes 
contain both β3 homomers and α1β3 heteromers. The membranes (30–100 pmol of receptor) 
were incubated in the absence (control) or presence of the protiated or deuterated version of 
ortho-propofol diazirine (3 μM, 30 μM or 100 μM) and irradiated with wavelengths >320 
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nm for 3 minutes. In the first set of experiments GABAA receptors were extracted in 2% 
TritonX-100 to preserve pentameric receptor structure and the α1β3 heteromers and β3 
homomers were separately purified by sequential affinity chromatography on Strep-tactin 
superflow plus resin™ (Qiagen) and Ni2+ NTA-agarose (Qiagen) beads. In two subsequent 
experiments, GABAA receptors were extracted from photolabeled membranes using 
denaturing conditions (2% SDS) to enhance the protein yield and increase mass 
spectrometric sequence coverage. The α1 and β3 subunits were separately purified by 
detergent dilution followed by sequential affinity chromatography with Strep-tactin 
superflow plus resin™ and Ni2+ NTA-agarose. In all of the experiments, the affinity-purified 
GABAA receptor subunits were delipidated, reduced and alkylated, and digested in-solution 
with endoproteases, employing a strategy that generates multiple small overlapping peptides 
from the TMDs by using multiple-timed chymotryptic digestions23. LC-MS analysis of the 
protein digests yielded MS2 spectra that provided unambiguous identification of 96% of the 
amino acids in β3 subunit including 95% of the residues in the TMD regions as well as 95% 
of the amino acids in the α1 subunit including 88% of the TMD residues (Supplementary 
Figs. 3 and 4 and Tables 1 and 2). The undetected sequences in the N-terminal domains 
contain glycosylation sequons (N-X-T) and are probably not detected because they are 
glycosylated.
MS2 spectra (Supplementary Dataset) from all samples were searched for peptides modified 
by the added mass of either the protiated or deuterated propofol diazirines. The only 
candidate peptides that satisfied our criteria for labeling (see Methods) were the doubly 
charged peptides m/z=632.299 and m/z=632.802 corresponding to the protiated and 
deuterated ortho-propofol diazirine-adducts of 260-TMoxiTTINTHL-268, a β3 peptide 
located near the extracellular end of TM2.
Diagnostic MS2 spectra of the protiated and deuterated adducts of TMoxiTTINTHL were 
identified in both the α1β3 heteromers and the β3 homomers. The MS2 spectra (Fig. 3a) 
contain fragment ions (y series) that identify the sequence of the peptide and localize the site 
of photoincorporation to either H267 or L268. The major features in the MS2 spectra (m/
z=326.148 and 327.151) correspond to internal ion fragments (H*) that definitively identify 
the site of protiated and deuterated propofol incorporation as H267 (Fig. 3b). The stable 
heavy isotope labeling greatly assisted in interpretation of the fragmentation spectra, as 
fragment ions containing the deuterated or protiated propofol adduct differed by a single 
mass unit, whereas fragments (e.g. b2 ions) that were not labeled had identical mass. The 
parent peptide, TMoxiTTINTHL (m/z=524.261, z=2) was also observed at a 
chromatographic retention time significantly earlier than the propofol adducts. Comparison 
of the intensities of the parent and adduct MS1 features was used to estimate the efficiency 
of labeling as 13% for both the protiated and deuterated adduct.
Previous studies based on site-directed mutagenesis or molecular modeling have suggested 
that M286 in β3-TM3 and M236 in α1-TM1 constitute two sides of a possible propofol 
binding site between the α1 and β3 subunits12,13,20. Unambiguous MS2 spectra of peptides 
containing both M286 and M236 were identified in our analyses. MS1 features with an m/z 
corresponding to the calculated propofol adduct of these peptides were not observed. Based 
on the intensities of the observed peptides (β3- 285-LMoxiGCF-289, β3-278-
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VKAIDMoxiYLMoxiGCF-289, α1-227-IQTYLPcIMT-236) and the signal-to-noise ratio of 
our spectra, MS1 features of the propofol adducts of these peptides should have been 
observed if they were photolabeled with efficiencies of more than 3%. Given that the 
efficiency might vary between sites, we cannot rule out these residues as candidates for 
additional sites of propofol binding.
We explored the location of the labeled H267 in the structure of the GABAA receptor using 
the homology model based (Supplementary Fig. 5) on the open state of an homologous 
glutamate-gated chloride channel28 that was described previously22. On inspection of the 
model it was clear that, immediately adjacent to H267 is a predominantly hydrophobic cleft 
opening out to a larger cavity at the top of, and between, the first and second transmembrane 
domains TM1 and TM2 (Fig. 3 c–e and Supplementary Fig. 6). This cavity essentially lies 
within a single β subunit, although there is also an interaction with the main-chain at the top 
of TM2 in the neighboring subunit. This cleft is open to the central ion pore, allowing drug 
access. Figure 3c shows a side view of a putative propofol binding site seen from the center 
of the pore, and Figure 3d shows a top view (with the extracellular domain removed for 
clarity) illustrating the position of the ortho-propofol diazirine molecules with respect to the 
four transmembrane domains. Five equivalent drug molecules are shown in this model of a 
β3 pentamer, but given that the binding site is essentially composed of amino acid side 
chains from a single β subunit, we would predict only two or three drug molecules would 
bind to the αβ or αβγ heteromers, depending on the number of β subunits present. Figure 3e 
illustrates the binding cavity as a surface, with the location of the labeled histidine indicated 
at the bottom of the pocket.
We next mutated the labeled H267 to an alanine to test the effects of this mutation on 
propofol modulation of the α1β3 receptor. The H267A mutation caused a significant 
reduction (p<0.01) in the GABA apparent affinity (Fig. 3f) as previously reported29, a 
significant reduction (p<0.05) in the extent to which ortho-propofol diazirine potentiated 
(Fig. 3g) the receptor (at a GABA concentration equivalent to the GABA EC60 for both the 
wild-type and mutant receptors), and a comparable reduction (Fig. 3h) in the ability of the 
drug to directly activate the receptor (p<0.01). We also mutated F221 to the more bulky 
amino acid, tryptophan, because the model predicted that this should partially occlude drug 
binding (Supplementary Fig. 6). The F221W mutation had only a small effect on the GABA 
EC50 (Fig. 3f), although there was a measureable picrotoxin-sensitive increase in baseline 
current, indicating some constitutive activity (16 ± 4% of the maximum GABA-induced 
current; n=6). This mutation, however, virtually eliminated (Fig. 3g) anesthetic-induced 
potentiation (P<0.01) and significantly (P<0.01) reduced direct anesthetic activation (Fig. 
3h).
DISCUSSION
If the binding site of a drug is to be determined using photolabeling, then one of the most 
important problems to overcome is the attachment of a photoreactive group that does not 
significantly alter the interaction of the drug with its targets. With the simple general 
anesthetic propofol, this is particularly challenging because few, if any, modifications are 
known which do not significantly reduce its anesthetic potency30. Furthermore, the GABAA 
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receptor, to which propofol binds, is affected by an extraordinarily diverse range of chemical 
compounds that almost certainly bind to a variety of distinct sites9. Thus, it is particularly 
important that any photoreactive propofol analogue is as similar as possible to propofol 
itself. That said, designing an analogue that is chemically stable and is capable of covalently 
labeling a protein binding site before an unproductive internal rearrangement occurs, is a 
challenge in itself.
A widely used photoreactive group is the trifluoromethyl diazirine moiety, which is a 
chemically stable group with an absorbance band centered around 350 nm, well away from 
the principal absorbance band of proteins (280 nm). Propofol analogues with this group 
substituted at the para and meta positions were either inefficient photolabels (with both 
solvents and human serum albumin), or did not closely mimic the effects of the parent 
compound propofol on GABAA receptors. An analogue with this group replacing one of the 
two isopropyl side chains at the ortho position, however, worked remarkably well, being 
both a highly efficient photolabel, as well as retaining the ability to directly activate and 
potentiate the GABAA receptor almost as well as propofol. We further validated the ortho-
propofol diazirine analogue as a propofol photolabel by showing that it labeled the two 
propofol binding sites that had been identified using X-ray crystallography25 (Fig. 2). Our 
results with human serum albumin, together with the functional and binding data on 
GABAA receptors, strongly suggest that any binding sites identified using the ortho-
propofol diazirine photolabel are likely to represent sites where propofol itself will bind.
Our labeling experiments with GABAA receptors, whether α1β3 heteromers or β3 
homomers, identified a single peptide (260-TMoxiTTINTHL-268) as being labeled, with the 
ortho-propofol diazirine photolabel attached to histidine 267. A binding site involving the β 
subunit might have been expected, given the comparable apparent affinities of the α1β3 
heteromers or β3 homomers to propofol3,4, although the absence of labeling in the α subunit 
cannot be taken as definitive proof that another site involving this subunit might not exist. If, 
for example, the diazirine group is surrounded by solvent, the protein might not be 
measurably labeled. Also, our label might react more efficiently with some amino acids than 
with others. The labeling of H267 in the β3 subunit, however, was robust and reproducible.
Using an homology model based on the crystal structure28 of the open state of the 
glutamate-gated chloride channel22, we have identified a plausible binding site for propofol, 
in a cavity close to the interface between the transmembrane region and the ligand-binding 
extracellular domain. Our only constraints were the requirement for an amphiphilic cavity 
large enough to accommodate the drug, and the necessity for the diazirine moiety to be in 
proximity to histidine 267. Other than this, we cannot be definitive about the detailed 
molecular architecture of the binding site, although we note that the amino acid side chains 
in the vicinity of our postulated binding site are similar between the GABAA receptor and 
the glutamate-gated chloride channel, indicating that the homology model in this region 
should be relatively reliable.
The mutation of H267 to an alanine caused changes in both GABA activation and drug 
modulation of the receptor (Fig. 3f–h), and this is certainly consistent with this amino acid 
forming part of an anesthetic binding site. More persuasively, our model predicted that the 
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mutation of F221, which lies at the back of the cavity, to a more bulky tryptophan would 
partially block the binding of propofol. Indeed, this mutation caused some constituitive 
activity, as if the residue were mimicking the anesthetic, but also virtually eliminated 
anesthetic potentiation, as well as reducing direct anesthetic activation (Fig. 3f–h). The 
histidine that we have labeled is on the opposite side of the helix from an amino acid 
N2652,12,18,31 in TM2 that is known to be a key determinant of anesthetic action. The drug 
also lies equally close to another anesthetic determinant, G21914,32 at the top of TM1. 
Having said this, however, given that multiple mutations throughout the receptor can affect 
its modulation by anesthetics and other drugs, we consider our mutagenesis results are 
consistent with our model, but not definitive. An additional possibility that is difficult to rule 
out completely is that the labeling of H267 reflects an inhibitory site in the channel pore. 
This would seem to be very unlikely because we observe robust labeling at concentrations of 
the photolabel (3 μM) which do not cause measurable channel inhibition.
The site we have identified does not overlap with the propofol site19 in GLIC (which is 
inhibited, rather than activated by propofol). Nor does it overlap with an inter-subunit site 
(that lies between TM3 in a β subunit and TM1 in an adjacent α subunit) that has been 
shown to bind etomidate by photolabeling33, and which has also been proposed as a likely 
propofol binding site12,13,20. As mentioned above, although we did not label this site, we 
cannot rule it out, and further experiments with other propofol photolabels34,35 may provide 
a complete picture.
The approach that we have employed to identify propofol binding sites in GABAA receptors 
has several advantages. Most importantly, photolabeling is performed in intact membranes, 
in which the receptor is in a native lipid environment. While the ideal condition might be to 
photolabel in an intact cell, GABAA receptors are more likely to be in a native conformation 
in membranes than in the detergent environment used in most anesthetic photolabeling 
studies. The binding sites that we have identified are thus unlikely to be artifacts of 
unnatural or denaturing conditions.
In summary, we have identified a novel binding site for the widely used intravenous general 
anesthetic propofol on its major target, the GABAA receptor expressed in intact membranes. 
We have shown the utility of using a combination of deuterated and protiated variants of 
ortho-propofol diazirine, combined with mass spectrometry, to identify unknown propofol 
binding sites on membrane receptors.
METHODS
Synthesis of ortho-propofol diazirine and its deuterated analogue
The synthesis of ortho-propofol diazirine is outlined in Supplementary Note. ortho-Propofol 
diazirine was stable for hours at room temperature in organic solvents. It showed no signs of 
decomposition by 19F NMR spectroscopy over a period of six months as a 250 mM solution 
in ethanol at −18°C. The deuterated analogue of ortho-propofol diazirine was prepared in a 
like manner from deuterated ortho-isopropylphenol (see Supplementary Note). The 
penultimate, methylated diazirine had the following distribution of deuterium by mass 
spectrometry: 34:43:23 d0:d1:d2.
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Electrophysiology
GABAA receptors formed from either α1β2γ2s or α1β3 subunits were transiently expressed in 
HEK 293 cells and currents were recorded using whole-cell patch clamping as described 
previously26. Extracellular solution (140 mM NaCl, 2.5 mM KCl, 2 mM MgCl2, 10 mM 
HEPES, 10 mM D-glucose, 1 mM CaCl2, pH 7.4) was used to perfuse the cells. Currents 
were recorded using borosilicate glass electrodes filled with intracellular solution (140 mM 
CsCl, 4 mM NaCl, 10 mM HEPES, 10 mM D-glucose, 5 mM EGTA, 0.5 mM CaCl2, 2 mM 
Mg-ATP, pH 7.3) with cells voltage clamped at −60 mV.
[35S]-TBPS binding to GABAA receptor β3 homomers
[35S]-TBPS binding was performed as previously described22,36. Briefly, aliquots of 
membranes prepared from SF9 cells expressing β3 homomeric GABAA receptors (final 
protein concentration, 20 μg ml−1) were resuspended in 100 mM KCl, 10 mM potassium 
phosphate, pH 7.5, containing 1 to 2 nM [35S]-TBPS (60–100 Ci mmol−1) and 2-μl aliquots 
of ortho-propofol diazirine in dimethylsulfoxide (final concentration 10 nM–100 μM), in a 
total assay volume of 1 ml. Values for the maximum binding level, Bmax, were determined 
by using 30 nM [35S]-TBPS. Control binding was defined as the binding observed in the 
absence of ortho-propofol diazirine. All assays contained 0.2% ethanol. Nonspecific binding 
was defined as binding observed in the presence of 200 μM picrotoxin. The [35S]-TBPS 
binding data were fitted to a Hill equation.
Anesthetic potency in rats
ED50 concentrations for propofol and ortho-propofol diazirine causing loss of righting reflex 
in male Sprague-Dawley rats (average weight 498 ± 33 g; mean ± sd) were determined. The 
anesthetic, dissolved in Intralipid (Sigma-Aldrich), was introduced via a 26-gauge tail-vein 
cannula and the animals were then placed in a cylinder rotating at 3 rpm. Loss of righting 
reflex was scored within one minute of injection and the data analyzed using the method of 
Waud24. All experiments were carried out in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986 and have been approved by the Ethical Review 
Committee of Imperial College London.
Labeling of human serum albumin
Fatty-acid-free human serum albumin was dissolved in 1 ml of phosphate buffered saline 
(137 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer, pH 7.4) at 10 mg ml−1 and 
incubated in a quartz cuvette with protiated or deuterated ortho-propofol diazirine at a 
concentration of 1.5 mM for 5 minutes in the dark. The sample was then continuously stirred 
while being irradiated for 120 seconds with light from a mercury-xenon arc lamp whose 
light had been filtered by reflection from a dichroic mirror (to remove the infrared) and by 
passing through an interference filter (λ > 320 nm). After photolabeling, the protein was 
denatured with guanidine hydrochloride, the di-sulfide bonds were reduced using 
dithiothreitol and their reformation blocked using iodoacetamide, and then the protein was 
digested with trypsin following dialysis26. The resulting peptides were then separated using 
HPLC and analyzed using mass spectrometry as previously described26.
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Membrane preparation and GABAA receptor photolabeling
Sf9 cells were used27 to express α1-streptag and β3-His8 GABAA receptor subunits, and 
membranes were prepared as described previously22 and stored at −80°C. For photolabeling, 
the membranes (0.5 mg protein ml−1) were suspended in 10 mM potassium phosphate 
buffer, 100 mM KCl, containing a cocktail of protease inhibitors including 4-(2-
aminoethyl)benzenesulfonyl fluoride, pepstatin A, N-[N-(L-3-trans-carboxyirane-2-
carbonyl)-L-leucyl]-agmatine (E-64), bestatin, leupeptin, and aprotinin. Following 
incubation with 3 μM, 30 μM or 100 μM protiated or deuterated ortho-propofol diazirine for 
60 minutes in the dark, the membrane samples were irradiated in a quartz cuvette for 3 min, 
using a photoreactor emitting light at >320 nm37.
Purification of GABAA Receptor subunits and preparation of peptides
After UV irradiation, membranes were collected by centrifugation at 130,000g for 45 min 
and resuspended in lysis buffer containing 1% (w/v) Triton X-100, 150 mM NaCl, 50 mM 
sodium phosphate, pH 7.5 for 120 min at 4°C. The solubilized proteins were loaded on a 
Strep-tactin™ superflow plus resin (Qiagen) column. After washing the column with lysis 
buffer, the proteins were eluted with 25 mM desthiobiotin in the lysis buffer. The lysate that 
passed through the Strep-tactin column was adjusted to an imidazole concentration of 40 
mM and loaded on a Ni2+-NTA agarose (Qiagen) column. The column was washed with 
lysis buffer containing 40 mM imidazole and proteins were eluted with 0.1% Triton X-100, 
500 mM imidazole, 25 mM sodium phosphate, 300 mM NaCl, pH 7.5. All procedures were 
conducted at 4°C in the presence of a protease inhibitor cocktail containing 4-(2-
aminoethyl)benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin. 
To separately purify α1 and β3 subunits, photolabeled membranes were solubilized in 2% 
SDS, 100 mM sodium phosphate buffer. The membrane lysate was then diluted to an SDS 
concentration of 0.2% with Triton X-100 lysis buffer and the α1 subunits were purified 
using Strep-tactin affinity chromatography. The lysate that passed through the Step-tactin 
columns was diluted to 0.1 % SDS, adjusted to 40 mM imidazole and applied to a Ni2+-
NTA agarose column for purification of β3 subunits as described above.
MS samples were prepared as previously described22. Briefly, purified α1 and β3 receptor 
subunits were concentrated on a 30,000 MW cutoff concentrator (Centricon) and 
precipitated using a 2D cleanup kit (GE Lifesciences). The proteins were delipidated, 
suspended in 100 μl of 8 M urea, 0.1% RapiGest (Waters), 100 mM Tris, pH 8.5, reduced 
and alkylated as previously described23. The samples were then digested with 1 μg of the 
endoproteinase Lys-C overnight at 37°C followed by trypsin overnight at 37°C, or 
endoproteinase chymotrypsin for 2, 6, or 18 h at room temperature. For trypsin digestion, 
the samples were diluted with 100 mM Tris, pH 8.5, to reduce the concentration of urea to 2 
M. For chymotrypsin digestion, the samples were diluted by 100 mM Tris, pH 8.5, to a 
concentration of 1 M urea, and CaCl2 was added to a final concentration of 10 mM. The 
digests were terminated by adding formic acid to a final concentration of 1% and incubating 
at 37°C for 30 min. Solid-phase extraction with NuTip C4 (Glygen) and porous graphite 
carbon (PGC) tips was used to remove salts from the sample using the previously described 
methods23. The resulting peptides were analyzed using nano-LC-MS with a hybrid mass 
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spectrometer consisting of a linear quadrupole ion trap and an orbitrap ELITE (Thermo 
Scientific).
Data Processing and Analysis
The LC-MS data files were processed using MASCOT Distiller (Matrix Science Inc.), with 
previously described settings23. The resulting MS2 centroid-calculated files were used to 
search (with MASCOT; Matrix Science Inc.) a customized database containing the sequence 
of all GABAA receptor subunits. The search was conducted with no enzyme specificity and 
allowed 5 missed cleavages, oxidation of Met, carbamidomethylation of Cys, and a protiated 
or deuterated ortho-propofol diazirine adduct at every amino acid as variable modifications, 
with a parent ion tolerance of 10 ppm and a fragment ion mass tolerance of 0.05 Daltons. 
Scaffold (Proteome Software Inc.) was used to validate MS2-based peptide identifications 
with the Protein Prophet algorithm module38. To determine the photolabeled peptide 
identity, seven criterion were used to verify the search results: 1) peptide prophet probability 
≥95%; 2) The photolabeled peptide parent ions were within 3 ppm mass error tolerance 
according to the instrument setting; 3) De Novo sequencing of fragmentation MS2 spectra, 
based on the theoretical fragmentation generated by using MS-Product (University of 
California, San Francisco, CA), support the peptide identity; 4) The same features of peptide 
parent ions (MS1) and fragmentation ions (MS2) were observed in both protiated and 
deuterated ortho-propofol diazirine -labeled samples with isotope distribution pattern in 
agreement with the presence of deuterium; 5) The retention time of protiated ortho-propofol 
diazirine-labeled peptides is similar to that of the deuterated ortho-propofol diazirine-labeled 
peptides; 6) The features of the labeled peptides were not observed in the non-labeled 
control samples at the corresponding retention time and 7) The photolabeled peptide and its 
non-labeled parent were in the same file and the parent had a shorter chromatographic 
retention time.
Statistical analysis
For the analysis of the electrophysiological data on the GABAA receptor mutants, one-way 
ANOVA was used to test for the level of significance between the data from wild-type and 
mutant receptors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of ortho-propofol diazirine
(a) The chemical structures of propofol (left) and ortho-propofol diazirine (1). (b) The 
percentage potentiation of GABA-evoked currents by propofol (3 μM; n=12), ortho-
propofol diazirine (5 μM: n=12), para-methylene-propofol diazirine (4; 50 μM; n=7) and 
meta-propofol diazirine (2; 200 μM; n=3). GABA (3 μM; EC7) was applied to HEK293 cells 
expressing α1β2γ2s GABAA receptors, and the current was recorded under whole-cell patch 
clamp. The inset shows a typical current trace during switches into GABA, in the presence 
and absence of 5 μM ortho-propofol diazirine. (c) UV absorption spectrum of ortho-
propofol diazirine in ethanol (0.2 mg ml−1). (d) Inhibition of [35S]-TBPS binding to 
GABAA β3 homomers by ortho-propofol diazirine. The IC50 concentration for inhibition of 
TBPS binding was 2.9 ± 0.4 μM (n=3). (e) The percentage potentiation of GABA-evoked 
currents by ortho-propofol diazirine acting on α1β3 GABAA receptor heteromers. The EC50 
concentration for potentiation was 1.7 ± 0.7 μM (n=10) with a Hill coefficient of 0.8±0.2 
and the maximum potentiation was 151 ± 18%. (The point at the highest drug concentration 
was excluded from the fit to the Hill equation.) (f) Quantal dose-response curves for 
propofol and ortho-propofol diazirine for loss of righting reflex in rats. The ED50 
concentrations for propofol and ortho-propofol diazirine were 4.7 ± 0.8 mg kg−1 (n=12) and 
14.7 ± 0.2 mg kg−1 (n=13) respectively. All error bars are standard errors of the mean and if 
not shown, were smaller than the size of the symbols.
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Figure 2. Labeling human serum albumin with ortho-propofol diazirine
Calculated and observed isotopic distributions for (a) unlabeled YTK peptide, (b) YTK 
peptide labeled with protiated ortho-propofol diazirine and (c) YTK peptide labeled with 
partially deuterated ortho-propofol diazirine. MS2 data for peptides YTK (d) and HKPK (e) 
with protiated ortho-propofol diazirine (black) and deuterated ortho-propofol diazirine (red). 
The asterisks denote the presence of photolabel bound to the peptide fragment. The two sites 
are illustrated in (f) with PR1 being in subdomain IIIA (dark blue) and PR2 being in 
subdomain IIIB (light blue). More detailed views are shown in (g) for PR1 where the labeled 
Y411 is shown and in (h) for PR2 where the labeled H535 is shown. Dashed lines mark the 
distances between the propofol molecules to Y411 (4.9 A) and to H535 (5.0 A).
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Figure 3. Labeling GABAA receptors with ortho-propofol diazirine
With both α1β3 heteromers and β3 homomers only a single amino acid, H267, was labeled. 
(a) MS2 data for the peptide 260-TMTTINTHL-268 labeled with the protiated ortho-
propofol diazirine (black) and the deuterated ortho-propofol diazirine (red) superimposed. 
(b) Fragmentation diagram showing that the MS2 data are consistent with the ortho-
propofol diazirine labeling the histidine side chain which subsequently rearranges as internal 
ions H* and TH* following fragmentation. (c) A view of our proposed propofol binding site 
seen from the center of the pore. Two neighboring subunits are shown in yellow and blue 
and a single ortho-propofol diazirine molecule is shown associated with the yellow subunit. 
(d) A view from the extracellular side of the receptor, but with the extracellular domain 
removed for clarity. The β3 homopentamer is shown with five equivalent ortho-propofol 
diazirine molecules bound. (e) A surface representation of our proposed propofol binding 
pocket with an ortho-propofol diazirine molecule sitting in the pocket close to H267 which 
is the amino acid that is photolabeled. (f) Electrophysiological data from α1β3 heteromers 
showing the effects of the mutations β3-H267A and β3-F221W on the GABA apparent 
affinity (n=21), (g) the extent to which 3 μM ortho-propofol diazirine potentiates a GABA-
evoked chloride current (at the GABA EC60) (n=4–10) and (h) the extent to which 10 μM 
ortho-propofol diazirine directly activates the receptor (n=4). All error bars are standard 
errors of the mean.
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